NANOP Stock Overview
A clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Nanobiotix S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.74 |
| 52 Week High | €5.74 |
| 52 Week Low | €5.74 |
| Beta | 1.24 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -13.42% |
| 5 Year Change | -61.16% |
| Change since IPO | -8.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| NANOP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -5.2% | 0.8% |
| 1Y | n/a | -20.1% | 6.6% |
Return vs Industry: Insufficient data to determine how NANOP performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how NANOP performed against the UK Market.
Price Volatility
| NANOP volatility | |
|---|---|
| NANOP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: NANOP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NANOP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 101 | Laurent Levy | www.nanobiotix.com |
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
Nanobiotix S.A. Fundamentals Summary
| NANOP fundamental statistics | |
|---|---|
| Market cap | €230.03m |
| Earnings (TTM) | -€58.78m |
| Revenue (TTM) | €6.74m |
34.1x
P/S Ratio-3.9x
P/E RatioIs NANOP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NANOP income statement (TTM) | |
|---|---|
| Revenue | €6.74m |
| Cost of Revenue | €0 |
| Gross Profit | €6.74m |
| Other Expenses | €65.52m |
| Earnings | -€58.78m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 100.00% |
| Net Profit Margin | -872.15% |
| Debt/Equity Ratio | -90.6% |
How did NANOP perform over the long term?
See historical performance and comparison